10 August 2023
The Medicines Patent Pool (MPP) is pleased to present its annual report for the year 2022. Through strategic partnerships and dedicated efforts, MPP expanded its reach, fostered innovation, and further strengthened its position as a leading force in ensuring access to essential medicines and health technologies in low- and middle-income countries.
Click Here to Access the 2022 Annual Report
Access Digital Version of MPP’s 2022 Annual Report
In summary we have:
The growth in 2022 was driven by breakthrough licence agreements in long-acting formulations, including cabotegravir with ViiV Healthcare and Medincell technology for malaria. Additionally, we achieved a significant milestone in the fight against COVID-19 by signing a licence for ensitrelvir fumaric acid with Japanese company Shionogi. MPP also demonstrated remarkable progress signing its first ever licence in addressing non-communicable diseases (NCDs) through a license agreement with Novartis for the cancer treatment nilotinib.
Furthermore, MPP fostered growth by engaging with a higher number of generic manufacturers. The number of generic manufacturers who had signed a licence agreement with MPP peaked in 2022, and we are delighted to see so many applications from different countries.
Moreover, MPP experienced an expansion in the number of partners and collaborators, that allowed us to leverage expertise, resources, and support for our mission. The mRNA Technology Transfer Programme also witnessed notable growth in funding, enabling the progamme to grow to enhance its capabilities in this crucial area of vaccine security in low- and middle-income countries.
Press and Media
The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.
To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.
MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.